Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | PAR 25 058

Frequently Asked Questions (FAQs)

What is the IGNITE program announcement PAR 25 058?

The Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program announcement PAR 25 058 is a National Institutes of Health (NIH) discretionary grant opportunity that supports early, practical translational research for potential neurotherapeutics. It is aligned with the National Institute of Neurological Disorders and Stroke (NINDS) mission area and is intended to fund preclinical studies that help determine whether a therapeutic agent shows enough real biological activity and supporting evidence to justify moving into more advanced development.

How does this opportunity relate to prior announcements?

This announcement is a reissue of PAR-21-122, meaning it continues a previously released funding opportunity with updated details under the new PAR 25 058 identifier.

What is the main purpose of this funding opportunity?

The core purpose is to reduce early development risk for neurotherapeutic candidates by funding key preclinical studies that establish whether the agent demonstrates sufficient biological activity and a plausible therapeutic signal. The focus is on practical translational evidence rather than basic discovery-only findings.

What types of studies are supported under this IGNITE notice?

This notice centers on neurotherapeutic agent characterization and in vivo efficacy studies. It emphasizes work such as pharmacokinetic (PK) and pharmacodynamic (PD) studies and efficacy testing in living systems (for example, disease-relevant in vivo models).

What does PK (pharmacokinetics) mean in the context of this FOA?

PK studies address what the body does to the therapeutic agent, including absorption, distribution, metabolism, and elimination. The FOA highlights the importance of understanding exposure in relevant tissues such as the brain, spinal cord, peripheral nerves, or muscle.

What does PD (pharmacodynamics) mean in the context of this FOA?

PD studies focus on what the therapeutic agent does to the body, such as target engagement, pathway modulation, and downstream biological effects. These experiments help connect the agent to a mechanistic or biological response relevant to neurological or neuromuscular disease.

What are in vivo efficacy studies for this opportunity?

In vivo efficacy studies are experiments that evaluate whether the agent produces meaningful benefit in an appropriate animal or other in vivo model. The intent is to connect PK/PD properties to functional outcomes in a disease-relevant context.

Is this funding meant for basic discovery research?

No. The intent is not simply to generate basic discovery findings. The FOA is focused on translational work that demonstrates sufficient biological activity and a plausible therapeutic signal to justify advancing the candidate into later development stages.

What award mechanism does this opportunity use?

The opportunity uses the R61/R33 phased award structure, which is designed to support milestone-driven progress from an initial phase into a subsequent phase as the project advances through defined translational steps.

Are clinical trials allowed under this FOA?

No. The announcement explicitly does not allow clinical trials. The supported work must remain on the preclinical side.

What kinds of therapeutic modalities are eligible?

The opportunity supports a range of therapeutic modalities, including small molecules, biologics, and other biotechnology-derived products. Examples described include a novel chemical entity, a repurposed compound with a new neurological indication, an antibody or protein therapeutic, or other engineered biologic approaches, as long as the work plan is focused on rigorous characterization and in vivo proof-of-concept.

What diseases or conditions should projects target?

Projects should be relevant to neurological or neuromuscular disorders and aligned with the NINDS mission space.

What is the larger program intent beyond this specific award?

The larger intent is to push projects to a point where they can meet entry criteria for later-stage translational pipelines, particularly the Blueprint Neurotherapeutics Network (BPN) or similar development programs. This FOA is meant to bridge the gap between an interesting therapeutic concept and the stronger evidence package needed for deeper development investment.

Who is eligible to apply?

Eligibility is broad. The FOA includes many types of U.S. governmental entities (state, county, city or township, and special district governments), independent school districts, and public housing authorities/Indian housing authorities. It also includes higher education institutions (public/state-controlled and private), nonprofit organizations (with and without 501(c)(3) status when not institutions of higher education), for-profit organizations (other than small businesses), small businesses, and a range of other eligible applicant categories including certain minority-serving institutions, eligible federal agencies, faith-based or community-based organizations, tribal governments not federally recognized, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities.

Are non-U.S. (foreign) entities eligible?

Yes. The eligibility section explicitly includes non-U.S. (foreign) entities among eligible applicants.

Are small businesses eligible?

Yes. Small businesses are explicitly included as eligible applicants.

Are for-profit organizations eligible?

Yes. For-profit organizations are eligible, with the note that eligible for-profits are "other than small businesses" because small businesses are listed as a separate eligible category (and are also eligible).

Are universities and colleges eligible?

Yes. Public and state-controlled institutions of higher education and private institutions of higher education are both eligible.

Are nonprofits without 501(c)(3) status eligible?

Yes. Nonprofit organizations without 501(c)(3) status are included as eligible when they are not institutions of higher education.

What is the CFDA number associated with this opportunity?

The opportunity is associated with CFDA number 93.853.

What is the award ceiling listed for this opportunity?

The source information lists an award ceiling of $750,000.

How many awards are expected?

The expected awards field is not specified in the provided source data.

What is the original closing date and creation date listed?

The original closing date is noted as 2024-11-03, and the creation date is listed as 2024-10-22.

Which federal agency administers this opportunity?

This is administered within NIH and aligned with the NINDS mission area.

What is meant by "agent characterization" in this FOA?

Based on the description provided, agent characterization includes generating practical preclinical data such as PK and PD evidence (including tissue exposure and biological effects like target engagement) to support a decision about whether the agent is ready to advance into more demanding development stages.

What kind of evidence is this FOA trying to generate overall?

The FOA is trying to generate a disciplined preclinical evidence package that demonstrates real biological activity and a plausible therapeutic signal, tying together PK/PD information with in vivo efficacy results in disease-relevant contexts.

What type of funding opportunity is this described as?

It is described as a NIH discretionary grant opportunity in the health activity category, using a grant funding instrument.